AKT1/AKT2/AKT3(phospho-Tyr315/316/312) Antibody

Catalog Number:

11501

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: P31749 P31751 Q9Y243
NCBI Protein: NP_001014431.1 NP_001617.1 NP_005456.1

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Peptide sequence around phosphorylation site of tyrosine 315/316/312 (P-E-Y(p)-L-A) derived from Human AKT1/AKT2/AKT3.

Purification:

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Specificity/Sensitivity:

The antibody detects endogenous level of AKT1/AKT2/AKT3 only when phosphorylated at tyrosine 315/316/312.

Applications:

WB IHC IF

Background:

General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. /General protein kinase capable of phosphorylating several known proteins. IGF-1 leads to the activation of AKT3, which may play a role in regulating cell survival. Capable of phosphorylating several known proteins. Truncated isoform 2/PKB gamma 1 without the second serine phosphorylation site could still be stimulated but to a lesser extent.

Nelms K, et al. (1999) Annu Rev Immunol. 17:701-738.
Malabarba M G, et al. (1996) Biochem. J. 319:865-872.
Hou J, et al. (1994) Science. 265:1701-1706.
Quelle F W, et al. (1995) Mol Cell Biol. 15: 3336-3343.

References:

appl_detail:

Predicted MW: 60kd
Western blotting: 1:500~1:1000
Immunohistochemistry: 1:50~1:100
Immunofluorescence: 1:100~1:200

Datasheet PDF